-0.000170735871606591 0 -0.00717090660747814 -0.00836605770872452 -0.0122929827556769 -0.0136588697285299 -0.00887826532354441 -0.0044391326617722
Sign Up Today X
Thanks for submitting the form.
Stockreport

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know [Yahoo! Finance]

Incyte Corporation (INCY)  More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $1.01 billion, while the same for earnings is pinned at $1.05 per share. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.) Let's see how things might have shaped up prior to the announcement. Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States and other marketed drugs. Its momentum is likely to have continued on the back of Jakafi, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]). However, competition from other approved drugs might have restricted sales growth potential to some extent. The Zacks Consensus Estimate for Jakafi's first-quarter sales is pegged at $661 million. Incyte also earns product royalty revenues from Novartis NVS for the commercialization of Jakafi in ex-U.S. markets. While [Read more]
IMPACT SNAPSHOT EVENT TIME: INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
INCY alerts
from News Quantified
INCY
NEWS
INCY
Earnings
INCY
Analyst Actions
INCY
SEC Filings
Stockreport

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know [Yahoo! Finance]

Incyte Corporation  (INCY) 
More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $1.01 billion, while the same for earnings is pinned at $1.05 per share. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.) Let's see how things might have shaped up prior to the announcement. Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States and other marketed drugs. Its momentum is likely to have continued on the back of Jakafi, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]). However, competition from other approved drugs might have restricted sales growth potential to some extent. The Zacks Consensus Estimate for Jakafi's first-quarter sales is pegged at $661 million. Incyte also earns product royalty revenues from Novartis NVS for the commercialization of Jakafi in ex-U.S. markets. While [Read more]
IMPACT SNAPSHOT
EVENT TIME:
INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS